Altered CD8+ T-cell responses when immunizing with multiepitope peptide vaccines

Journal of Immunotherapy

Volumn 29, Issue 2, 2006, Pages 224-231

  Rosenberg, Steven A ^a   Sherry, Richard M ^a   Morton, Kathleen E ^a   Yang, James C ^a   Topalian, Suzanne L ^a   Royal, Richard E ^a   Kammula, Udai S ^a   Restifo, Nicholas P ^a   Hughes, Marybeth S ^a   Schwarz, Susan L ^a   Ngo, Lien T ^a   Mavroukakis, Sharon A ^a   White, Donald E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Melanoma; Peptides; Vaccines

Indexed keywords

CD8 ANTIGEN; FREUND ADJUVANT; MONOPHENOL MONOOXYGENASE; PEPTIDE; VACCINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; APHERESIS; ARTICLE; CANCER; COMPETITIVE INHIBITION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENSITIZATION; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; RECURRENCE; TREATMENT OUTCOME;

EID: 33646779561     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000190399.98802.10     Document Type: Article

References (21)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
2. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:876-886.
3. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A*0210 binding residues. J Immunol. 1996;157:2539-2548.
4. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
6. Ribas A, Butterfield LH, Glaspy JA, et al. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003;21:2415-2432.
7. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016-4026.
8. Lu J, Higashimoto Y, Appella E, et al. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol. 2004;172:4572-4582.
9. Valmori D, Dutoit V, Ayyoub M, et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 2003;3:15.
10. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175:6169-6176.
11. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-373.
12. Nishimura MI, Avichezer D, Custer MC, et al. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res. 1999;59:6230-6238.
13. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321-327.
14. 280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012-3024.
15. Schaed SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2004;8:967-972.
16. Scheibenbogen C, Schmittel A, Keilholz U, et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother. 2000;23:275-281.
17. Wang F, Bade E, Kuniyoshi C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res. 1999;5:2756-2765.
18. Smith JW, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 2004;21:1562-1573.
19. Thompson LW, Garbee CF, Hibbitts S, et al. Competition among peptides in melanoma vaccines for binding to MHC molecules. J J Immunother. 2004;27:425-431.
20. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med. 1996;183:527-534.
21. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999;17:51-88.